Serán Bioscience Secures Growth Investment

Serán Bioscience, a contract development and manufacturing organization (CDMO) specializing in development, analytical and manufacturing solutions for pharmaceutical and biotechnology companies, has announced a growth investment led by Biospring Partners and existing investors, as well as Serán’s executive leadership—enabling the Company to accelerate its strategic expansion across clinical to commercial services.

With this investment, Serán will expand its service offerings to provide enabling and accelerated solutions for clients from early development to commercial supply in direct response to growing client demand for capabilities in particle engineering and commercial-scale manufacturing technologies.

A centerpiece of Serán’s expansion strategy is the construction of its new commercial facility to be completed in 3Q 2027. Purpose-built to meet the industry’s most demanding technical specifications, the multi-suite facility will support OEB4 manufacturing for oral, pulmonary, and other delivery modalities with commercial-scale particle engineering solutions, including spray drying, and nano-milling. In addition, this new facility will also provide comprehensive finished dose capabilities including granulation, tableting, coating, encapsulation, and specialized dry powder filling for inhalation products across immediate and modified release profiles.

This greenfield expansion seamlessly integrates with Serán’s recently completed adjacent packaging and logistics facility which will provide fully validated packaging, labeling, unit-level serialization, and global cold-chain distribution.

“This investment is a significant milestone in Serán’s evolution as we rapidly scale our clinical manufacturing operations to support launches of new medicines, as well as serve new clients seeking a state-of-the-art commercial manufacturing partner,” said Dan Smithey, Co-Founder and CEO of Serán. “With the invaluable backing of Biospring Partners, alongside our long-standing partners at Bain Capital and Vivo Capital, we are well-positioned to complete our greenfield commercial facility on schedule and deliver seamless, life-changing therapies from early-phase discovery through commercial launch.”

Serán has over 200 team members and will hire as many as 150 additional employees as the commercial expansion progresses.